DNA blood test for pancreatic cancer prognosis and treatment
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a suspicious mass in your pancreas seen on imaging, and you are scheduled for surgery or a biopsy to confirm cancer.
- Your tumor can be measured on a CT scan (at least 1 cm in size).
- You are able to provide a blood sample and a piece of tumor tissue.
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your blood counts and liver/kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial is studying a blood test that looks for tumor DNA (ctDNA) to see if it can help predict how well treatment is working in people with pancreatic cancer that hasn't spread. It is for patients getting chemotherapy before possible surgery.
This study uses stored blood samples from people at higher risk for pancreatic cancer (due to family history or certain pancreatic cysts) to see if a simple blood test can detect the disease early or help monitor it over time.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.